Latest Clinical Papers
Impact of EOB-MRI on the outcome of patients with pancreatic cancer in real-world settings
Adding EOB-MRI before initial treatment significantly improves overall survival in pancreatic cancer patients who do not undergo surgery, highlighting its value in early detection of metastases and informed treatment planning.
2024
Added Value of Liver MRI in Patients Eligible for Surgical Resection or Ablation of Colorectal Liver Metastases Based on CT: A Systematic Review and Meta-Analysis
Liver MRI alters the pre-interventional treatment plan for approximately 20% of patients with colorectal liver metastases, demonstrating significant clinical value over CT alone.
2024
Intrahepatic mass-forming cholangiocarcinoma: is there additional prognostic value in using Gd-EOB enhanced MRI?
Gadoxetic acid-enhanced MRI identifies hypointense and significantly-retaining subtypes of intrahepatic mass-forming cholangiocarcinomas, with the hypointense subtype associated with more frequent intrahepatic metastases and an infiltrative growth pattern.
2024
MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicenter, prospective, diagnostic accuracy trial
Adding contrast-enhanced MRI to CT significantly impacted treatment plans for patients with colorectal liver metastases, guiding more accurate decisions for local therapy
2024
Additional nodules detected using EOB-MRI in patients with resectable single hepatocellular carcinoma: An implication for active treatment strategy
Aggressive treatment (resection/RFA) for additional nodules detected on EOB-MRI in HCC patients results in comparable long-term survival to that of solitary HCC cases.
2024
Prognostic value of baseline MRI features in patients treated with thermal ablation for hepatocellular carcinoma
Presence of peritumoral hypointensity on baseline hepatobiliary phase emerges as a predictor for the time-to-recurrence in early-stage hepatocellular carcinoma patients treated with thermal ablation.
2024
Hepatobiliary-phase (HBP) gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid MRI (Gd-EOB-DTPA) for pretreatment prediction of efficacy-to-standard-therapies based on Barcelona Clinic Liver Cancer algorithm: an up-todate review
The HBP in EOB-MRI reflecting molecular and pathological factors, may predict hepatocellular carcinoma (HCC) treatment efficacy and guide treatment choices.
2023
A multivariate model based on gadoxetic acidenhanced MRI using Li-RADS v2018 and other imaging features for preoperative prediction of dualphenotype hepatocellular carcinoma (DPHCC)
Gd-EOB-DTPA MRI effectively differentiates between DPHCC and non-DPHCC.
2023
Magnetic resonance imaging-based risk factors of hepatocellular carcinoma after direct-acting antiviral therapy: multicenter observational study
Gd-EOB-DTPA MRI could predict the development of hypervascular HCC following HCV DAA therapy.
2023
